U.S. FDA APPROVES IGALMI® AS FIRST AT-HOME ACUTE TREATMENT FOR AGITATION ASSOCIATED WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, OR BIPOLAR I OR II DISORDER IN ADULTS

Reuters · 2d ago

Please log in to view news